This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dewan, M. Z.
Right arrow Articles by Morishita, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dewan, M. Z.
Right arrow Articles by Morishita, K.

 Previous Article  |  Next Article 

Journal of Virology, December 2008, p. 11958-11963, Vol. 82, No. 23
0022-538X/08/$08.00+0     doi:10.1128/JVI.01149-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Critical Role for TSLC1 Expression in the Growth and Organ Infiltration of Adult T-Cell Leukemia Cells In Vivo{triangledown}

M. Zahidunnabi Dewan,1,2,{dagger} Naofumi Takamatsu,3 Tomonori Hidaka,4 Kinta Hatakeyama,5 Shingo Nakahata,3 Jun-ichi Fujisawa,6 Harutaka Katano,7 Naoki Yamamoto,1,2* and Kazuhiro Morishita3*

Department of Molecular Virology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan,1 AIDS Research Center, National Institute of Infectious Disease, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan,2 Department of Medical Sciences,3 Department of Internal Medicine,4 Department of Pathology, Faculty of Medicine, University of Miyazaki, Kiyotake, Miyazaki, Japan,5 Department of Microbiology, Kansai Medical University, Moriguchi, Osaka, Japan,6 Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan7

Received 2 June 2008/ Accepted 15 September 2008


arrow
ABSTRACT
 
Adult T-cell leukemia (ATL) is associated with human T-cell leukemia virus type 1 infection. The tumor suppressor lung cancer 1 (TSLC1) gene was previously identified as a novel cell surface marker for ATL, and this study demonstrated the involvement of TSLC1 expression in tumor growth and organ infiltration of ATL cells. In experiments using NOD/SCID/{gamma}cnull mice, both leukemia cell lines and primary ATL cells with high TSLC1 expression caused more tumor formation and aggressive infiltration of various organs of mice. Our results suggest that TSLC1 expression in ATL cells plays an important role in the growth and organ infiltration of ATL cells.


arrow
TEXT
 
Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of an aggressive form of CD4+ T-cell leukemia termed adult T-cell leukemia (ATL) (7, 14, 18). Carriers of HTLV-1 have been identified in a number of locations throughout the world, including parts of Africa; Papua New Guinea; specific regions in Europe including Romania; parts of South America including northern Brazil, Peru, northern Argentina, and Colombia; and the southern part of Kyushu in Japan (17). Common findings in patients with ATL include enlargement of peripheral lymph nodes, hepatomegaly, splenomegaly, skin infiltration, and hypercalcemia. The Tax gene is a unique viral gene thought to play a central role in HTLV-1-induced transformation. It is responsible for transactivation of the HTLV-1 long terminal repeat (5, 16) and numerous cellular genes involved in T-cell activation and growth, including those encoding interleukin-2 (IL-2) (11) and the {alpha} chain of IL-2 receptor (IL-2R{alpha}) (CD25, Tac) (1, 2). The long latency of ATL development suggests that multiple genetic events accumulate in HTLV-1-infected cells; however, the precise molecular mechanisms of ATL leukemogenesis following HTLV-1 infection have not been fully elucidated.

The tumor suppressor lung cancer 1 gene (TSLC1) at chromosome 11q23 has been identified as a tumor suppressor gene in non-small-cell lung cancer (9, 13). In contrast, it was recently found to be highly and ectopically expressed in acute-type ATL cells, most ATL cell lines, and HTLV-1-infected T-cell lines (15). Enforced expression of TSLC1 in ATL-derived ED-40515(–) cells resulted in higher aggregations and binding abilities in a human umbilical vein endothelial cell line (HUVEC). These results suggest that TSLC1 might contribute to tumor growth by enhancing aggregation after infiltration and migration outside blood vessels. Since the role of TSLC1 overexpression in the course of tumor growth and organ infiltration of ATL cells remains to be fully elucidated, we investigated the direct involvement of TSLC1 in the growth and infiltration of leukemia cells using C57BL/6J and NOD-SCID/{gamma}cnull (NOG) mice (4, 8).

In order to analyze the tumorigenicity of TSLC1 expression in leukemia cells, a murine IL-2-independent T-lymphoma cell line (EL4) injected into the intraperitoneum of syngeneic C57BL/6J mice was used as a model for ATL. EL4 cells were transfected with a pcDNA3 expression plasmid containing TSLC1, and transformant cells were selected by a limiting-dilution method in the presence of G-418. We also used EL4 cells expressing a green fluorescent protein-Tax fusion protein (EL4/GAX) (6) and parental EL4 (EL4/p) as a control. Expression of Tax protein in EL4 cells, a 38-kDa band of Tax protein in HUT102 cells, and a 64-kDa band of green fluorescent protein-Tax fusion protein in EL4/GAX cells were all detected by Western blot analysis (Fig. 1A). Expression of a TSLC1 protein in EL4/TSLC1 cells was also shown on Western blot analysis with KK1, an ATL cell line expressing TSLC1 (12) (Fig. 1B). In an in vitro cell growth assay, 2 x 104 cells were incubated, and their growth was analyzed by direct counting with trypan blue dye staining. EL4 and EL4/TSLC1 cells showed nearly identical proliferation profiles in vitro, while Tax-expressing EL4 cells proliferated more slowly (Fig. 1C). This difference in cell growth might be caused by different expression vectors. In an in vivo growth assay, 2 x 106 cells of each cell line were injected into the peritoneal cavity of C57BL/6J mice: eight mice for EL4 cells as controls, 13 mice for EL4/TSLC1 cells, and eight mice for EL4/GAX cells. All of the mice died of tumor invasion of various organs with ascitic fluids in 40 to 120 days. The median survival time of the control mice injected with EL4 cells or EL4/GAX cells was 72 days. The mice with EL4/TSLC1 cells, however, died within 60 days, with a median survival time of 41 days (Fig. 1D). The phenotypes of the control mice and the EL4/TSLC1 mice were almost identical with invasion of tumors into various organs. Organ metastasis of tumor cells in three EL4/TSLC1-inoculated mice, two EL4-inoculated mice, and one EL4/GAX-inoculated mouse was analyzed and evaluated with hematoxylin-eosin staining. The liver was one of the major sites of metastasis in all three of the EL4/TSLC1-inoculated mice by histopathological analysis but not in the two EL4-inoculated mice or the EL4/GAX-inoculated mouse (Fig. 1E). These results support the role of TSLC1 overexpression in T-lymphoma cells as one of an aggressive factor in the development of leukemia/lymphoma.


Figure 1
View larger version (44K):
[in this window]
[in a new window]

  		FIG. 1. Transplantation of EL4 T-cell lymphoma cells expressing TSLC1 shortened the life span of syngeneic mice. (A) Expression of Tax protein in HUT102, EL4, EL4/GAX, and EL4/TSLC1 cells was detected by Western blot analysis. Expression of β-actin protein (ACTB) was used as a loading control. (B) Expression of TSLC1 protein in KK1, EL4, EL4/GAX, and EL4/TSLC1 cells was detected by Western blot analysis. Expression of β-actin protein (ACTB) was used as a loading control. (C) Cell numbers in a growth curve are shown for an average of three independent counts, and standard deviations are indicated as error bars. (D) Survival curves of C57BL/6 mice inoculated in the abdominal cavity with EL4, EL4/GAX, or EL4/TSLC1 cells. Cumulative survival rates were calculated by the Kaplan-Meier method and compared using a log-rank test. (E) Liver sections from all mice were stained with hematoxylin-eosin. The regions of liver metastasis (arrow) were seen in liver sections from mice inoculated with EL4/TSLC1 cells but not shown in the liver sections from the mice inoculated with EL4 or EL4/GAX cells. Magnification, x100; bars, 400 µm.

In order to investigate the possibility that overexpression of TSLC1 promotes tumor growth and/or infiltration in vivo, ATL-derived ED-40515(–) cells (10) were injected into NOG mice. Since expression of TSLC1 in ED-40515(–) cells is severely reduced by promoter methylation, they were transfected with either a TSLC1 expression plasmid (pcDNA3/TSLC1) or a mock plasmid (pcDNA3/Neo). ED/TSLC1 and ED/Neo cells were identified by selection with G-418. High levels of TSLC1 expression were verified in the ED/TSLC1 cells, but not in the ED/Neo cells, by Western blot analysis (Fig. 2A). The ED/TSLC1, ED/Neo, and ED-40515(–) cell lines all showed the same proliferation profile in vitro (Fig. 2B). Cells (10 x 106) were inoculated subcutaneously into the postauricular region of NOG mice, which permitted the observation of tumor growth macroscopically and the measurement of tumor size over a relatively short time (3). The ED/TSLC1 cell lines caused greater formation of larger tumors than did the ED/Neo and ED-40515(–) cell lines (Fig. 2C). The development of clinical signs of near-death (e.g., piloerection, weight loss, and cachexia) in mice at the time of killing was also more prevalent with the ED/TSLC1 cell line. These results suggest that TSLC1 expression in ATL cells enhances in vivo tumor growth in NOG mice.


Figure 2
View larger version (61K):
[in this window]
[in a new window]

  		FIG. 2. Involvement of TSLC1 expression in tumor growth and infiltration of leukemia cells in NOG mice. (A) Expression of TSLC1 in KK1, ED-40515(–), ED/Neo, or ED/TSLC1 cell lines was detected by Western blot analysis. Expression of β-actin protein (ACTB) was used as a loading control. (B) Cell growth curves of ED-40515(–), ED/Neo, and ED/TSLC1 cell lines are shown for an average of three independent counts, and standard deviations are indicated as error bars. (C) Tumor volumes of mice inoculated subcutaneously with ED/TSLC1, ED/Neo, or ED-40515(–) cells after 21 days are shown as the means ± standard errors of the means for five mice in each group. Statistical analysis was done with a Student t test. (D and E) The pictures shown were derived from gross photographs of the sacrificed mice at 1 month after intravenous inoculation of ED/Neo (D) or ED/TSLC1 (E) cells. (F) Immunohistochemical staining for TSLC1 protein in liver metastases of the mice inoculated intravenously with ED/TSLC1 cells is shown. An arrow indicates a tumor mass with strong staining with a rabbit anti-TSLC1 antibody; however, the same mass shows no staining with rabbit immunoglobulin (Ig) as a negative control. Magnification, x100; bars, 400 µm.

Since the mice died within 4 weeks after subcutaneous inoculation of leukemia cells due to heavy tumor burden, 2 x 106 ED/TSLC1 or ED/Neo cells were intravenously injected into six NOG mice in order to investigate their capacity for invasion of various organs. After 1 month, we sacrificed the mice to determine the extent of organ invasion. Macroscopically, all of the mice injected with ED/TSLC1 cells (six/six) showed severe liver invasion with swelling of the ovaries. None of the mice injected with ED/Neo cells showed liver invasion, but they did show ovarian involvement (Fig. 2D and E). Microscopically, all of the mice inoculated with ED/TSLC1 cells showed severe and massive liver and lung invasions. On the other hand, only one of six mice inoculated with ED/Neo cells showed a large amount of liver metastasis (Table 1). TSLC1 expression in tumor cells infiltrating the liver was confirmed by immunohistochemical staining (Fig. 2F). Thus, overexpression of TSLC1 in ATL cells might enhance organ invasion, and particularly invasion of the liver and lung.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Invasion scores of mice inoculated with ED/Neo or ED/TSLC1 cells

Next, we examined whether primary ATL cells with various levels of expression of TSLC1 could efficiently grow and infiltrate various organs in NOG mice. TSLC1-positive primary ATL cells (2 x 107) from five acute-type and five chronic-type ATL patients were inoculated subcutaneously into the postauricular region of NOG mice (Table 2). All of the mice developed clinical signs of near-death (e.g., piloerection, weight loss, and cachexia) 6 to 8 weeks after inoculation, in addition to the enlargement of the lymph nodes, spleen, lungs, and liver. Microscopically, ATL cells invaded various organs of all ATL-bearing NOG mice to different degrees. Based on results of immunohistochemical staining for TSLC1, all invading leukemia cells expressed TSLC1 protein, compared with no TSLC1 expression in these organs in control NOG mice (Table 2 and Fig. 3A). The dispersion diagram for the levels of invasion and the levels of TSLC1 expression in the leukemia cells showed a correlation coefficient of 0.714, suggesting that there was a moderate correlation between invasive capability and the level of TSLC1 expression (Fig. 3B). Thus, TSLC1 could aid in the formation of a rapidly growing large tumor and massive infiltration of ATL cells into various organs in NOG mice. Since TSLC1 is expressed in various types of ATL cells, including smoldering and chronic types, it might be a promising target for the development of a new anti-ATL therapy. The NOG mouse model system described in the present study could provide a novel means by which to understand and investigate the further importance of TSLC1 in ATL progression.


View this table:
[in this window]
[in a new window]

  		TABLE 2. Clinical characteristics of patients and pathological findings of organ invasiona


Figure 3
View larger version (84K):
[in this window]
[in a new window]

  		FIG. 3. Growth and infiltration of primary ATL cells in various organs of NOG mice based on TSLC1 expression. (A) Immunohistochemical staining of various organs of NOG mice inoculated with leukemia cells from patient 6, 8, 9, or 10 is shown with the use of rabbit anti-TSLC1 antibody or rabbit immunoglobulin (Ig) as a negative control. Sections from patients 8 and 10 showed severe invasion (invasion score, 3) and dense staining for TSLC1 (expression score, 3), while sections from patients 6 and 9 showed mild invasion (invasion score, 1) and light staining for TSLC1 (expression score, 1). Liver and lung sections from control NOG mice were used as negative controls, and a lymph node from an ATL patient was used as a positive control. Magnification, x400; bars, 100 µm. (B) The diagram of dispersion between mean values of each invasion score and scores for TSLC1 expression in each NOG mouse inoculated with primary ATL cells showed moderate correlation (R = 0.714).


arrow
ACKNOWLEDGMENTS
 
We thank S. Ichinose of the Instrumental Analysis Research Center; S. Endo of the Animal Research Center, Tokyo Medical and Dental University; and Y. Sato of the National Institute of Infectious Diseases for her excellent technical assistance. Anti-Tax (MI73) antibody was the kind gift of Y. Namba and M. Matsuoka (Institute for Virus Research, Kyoto University).

Supported by grants from the Ministry of Education, Science, and Culture; the Ministry of Health, Labor, and Welfare; and Human Health Science of Japan.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address for Naoki Yamamoto: AIDS Research Center, National Institute of Infectious Disease, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. Phone: 81-3-5285-1111. Fax: 81-3-5285-1165. E-mail: nyama{at}nih.go.jp. Mailing address for Kazuhiro Morishita: Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Kiyotake, Miyazaki, Japan. Phone: 81-9-8585-0985. Fax: 81-9-8585-2401. E-mail: kmorishi{at}med.miyazaki-u.ac.jp Back

{triangledown} Published ahead of print on 15 October 2008. Back

{dagger} Present address: Department of Pathology, New York University School of Medicine, 550 First Avenue, New York, NY 10016. Back


arrow
REFERENCES
 
    1
  1. Ballard, D. W., E. Bohnlein, J. W. Lowenthal, Y. Wano, B. R. Franza, and W. C. Greene. 1988. HTLV-I tax induces cellular proteins that activate the B element in the IL-2 receptor gene. Science 241:1652-1655.[Abstract/Free Full Text]
    2. 2
  2. Cross, S. L., M. B. Feinberg, J. B. Wolf, N. J. Holbrook, F. Wong-Staal, and W. J. Leonard. 1987. Regulation of the human interleukin-2 receptor chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. Cell 49:47-56.[CrossRef][Medline]
    3. 3
  3. Dewan, M. Z., K. Terashima, M. Taruishi, H. Hasegawa, M. Ito, Y. Tanaka, N. Mori, T. Sata, Y. Koyanagi, M. Maeda, Y. Kubuki, A. Okayama, M. Fujii, and N. Yamamoto. 2003. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/c{gamma}null mice: suppression by an inhibitor against NF-{kappa}B. J. Virol. 77:5286-5294.[Abstract/Free Full Text]
    4. 4
  4. Dewan, M. Z., J. N. Uchihara, K. Terashima, M. Honda, T. Sata, M. Ito, N. Fujii, K. Uozumi, K. Tsukasaki, M. Tomonaga, Y. Kubuki, A. Okayama, M. Toi, N. Mori, and N. Yamamoto. 2006. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 107:716-724.[Abstract/Free Full Text]
    5. 5
  5. Felber, B. K., H. Paskalis, C. Kleinman-Ewing, F. Wong-Staal, and G. N. Pavlakis. 1985. The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats. Science 229:675-679.[Abstract/Free Full Text]
    6. 6
  6. Furuta, R. A., K. Sugiura, S. Kawakita, T. Inada, S. Ikehara, T. Matsuda, and J. Fujisawa. 2002. Mouse model for the equilibration interaction between the host immune system and human T-cell leukemia virus type 1 gene expression. J. Virol. 76:2703-2713.[Abstract/Free Full Text]
    7. 7
  7. Hinuma, Y., K. Nagata, M. Hanaoka, M. Nakai, T. Matsumoto, K. I. Kinoshita, S. Shirakawa, and I. Miyoshi. 1981. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. USA 78:6476-6480.[Abstract/Free Full Text]
    8. 8
  8. Ito, M., H. Hiramatsu, K. Kobayashi, K. Suzue, M. Kawahata, K. Hioki, Y. Ueyama, Y. Koyanagi, K. Sugamura, K. Tsuji, T. Heike, and T. Nakahata. 2002. NOD/SCID/.cnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100:3175-3182.[Abstract/Free Full Text]
    9. 9
  9. Kuramochi, M., H. Fukuhara, T. Nobukuni, T. Kanbe, T. Maruyama, H. P. Ghosh, M. Pletcher, M. Isomura, M. Onizuka, T. Kitamura, T. Sekiya, R. H. Reeves, and Y. Murakami. 2001. TSLC1 is a tumor suppressor gene in human non-small cell lung cancer. Nat. Genet. 27:427-730.[CrossRef][Medline]
    10. 10
  10. Maeda, M., A. Shimizu, K. Ikuta, H. Okamoto, M. Kashihara, T. Uchiyama, T. Honjo, and J. Yodoi. 1985. Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia. Analysis of T cell receptor gene rearrangement. J. Exp. Med. 162:2169-2174.[Abstract/Free Full Text]
    11. 11
  11. Maruyama, M., H. Shibuya, H. Harada, M. Hatakeyama, M. Seiki, T. Fujita, J. Inoue, M. Yoshida, and T. Taniguchi. 1987. Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering. Cell 48:343-350.[CrossRef][Medline]
    12. 12
  12. Masuda, M., M. Yagita, H. Fukuhara, M. Kuramochi, T. Maruyama, A. Nomoto, and Y. Murakami. 2002. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion J. Biol. Chem. 277:31014-31019.[Abstract/Free Full Text]
    13. 13
  13. Murakami, Y., T. Nobukuni, K. Tamura, T. Maruyama, T. Sekiya, Y. Arai, H. Gomyou, A. Tanigami, M. Ohki, D. Cabin, P. Frischmeyer, P. Hunt, and R. H. Reeves. 1998. Localization of tumor suppressor activity important in non-small cell lung carcinoma on chromosome 11q. Proc. Natl. Acad. Sci. USA 95:8153-8158.[Abstract/Free Full Text]
    14. 14
  14. Poiesz, B. J., F. W. Ruscetti, A. F. Gazdar, P. A. Bunn, J. D. Minna, and R. C. Gallo. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 77:7415-7419.[Abstract/Free Full Text]
    15. 15
  15. Sasaki, H., I. Nishikata, T. Shiraga, E. Akamatsu, T. Fukami, T. Hidaka, Y. Kubuki, A. Okayama, K. Hamada, H. Okabe, Y. Murakami, H. Tsubouchi, and K. Morishita. 2005. Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute type of adult T-cell leukemia. Blood 105:1204-1213.[Abstract/Free Full Text]
    16. 16
  16. Sodroski, J. G., C. A. Rosen, and W. A. Haseltine. 1984. Transacting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science 225:381-385.[Abstract/Free Full Text]
    17. 17
  17. Yamaguchi, K., and T. Watanabe. 2002. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int. J. Hematol. 76:240-245.[Medline]
    18. 18
  18. Yoshida, M., I. Miyoshi, and Y. Hinuma. 1982. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl. Acad. Sci. USA 79:2031-2035.[Abstract/Free Full Text]

Journal of Virology, December 2008, p. 11958-11963, Vol. 82, No. 23
0022-538X/08/$08.00+0     doi:10.1128/JVI.01149-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hasstedt, S. J., Bezemer, I. D., Callas, P. W., Vossen, C. Y., Trotman, W., Hebbel, R. P., Demers, C., Rosendaal, F. R., Bovill, E. G. (2009). Cell adhesion molecule 1: a novel risk factor for venous thrombosis. Blood 114: 3084-3091 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dewan, M. Z.
Right arrow Articles by Morishita, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dewan, M. Z.
Right arrow Articles by Morishita, K.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»